For these reasons, the efficacy of alternative vasodilators should be assessed in patients with severe heart failure. Among such agents, the alpha blocker phentolamine has been shown to exert beneficial hemodynamic effects when given intravenously to patients with heart failure. Previous studies have usually assessed the effects of phentolamine infused at a single dose. This study evaluates the acute hemodynamic effects of intravenous phentolamine infused at increasing dose levels in 19 patients with stable, chronic low output cardiac failure.
Materials, Methods and Procedures
Informed consent was obtained from each patient before the study.
All 19 patients studied were hospitalized for treat-ment of severe cardiac failure. There were 18 males and one female. Ages ranged from 36-76 years, with an average of 57 years. Heart failure was considered to be the result of atherosclerotic heart disease in nine patients, primary myocardial disease in eight patients and hypertension in one patient. One patient had left ventricular dysfunction persisting after mitral valve replacement. Although several patients had murmurs of mitral and/or tricuspid regurgitation, valvular disease was not considered to be a major cause of heart failure. All patients had received digitalis and diuretic therapy before the study. These medications were usually omitted the morning of the study. The patients were brought to the special hemodynamic research unit on the morning of the study. They were in a fasting state and had not received specific premedication. A #7F thermal dilution Swan-Ganz catheter was inserted into an antecubital vein and advanced under fluoroscopic control until the catheter tip was situated in the right or left pulmonary artery. The tip was positioned to yield a reliable wedge pressure (WP) waveform when the balloon was inflated, and pulmonary artery systolic pressure (PASP) and pulmonary artery diastolic pressure (PADP) waveform when the balloon was deflated. A satisfactory WrP could not be obtained in two patients, and their PADP was utilized as an index for left ventricular filling pressure (LVFP). Right atrial pressure (RAP) was measured from the proximal lumen. Cardiac output (CO) was determined by averaging three or more thermal dilution curves obtained by injecting 10 cc of 00 C saline into the right atrium. A Model 9500 Edwards Laboratory CO computer was used to give on-line readout of CO. Arterial systolic pressures (ASP) and arterial diastolic pressures (ADP) were measured from an indwelling cannula in the radial or brachial artery. Pressures were measured from Statham 23DB transducers leveled at the midchest position. Mean pulmonary arterial pressures (MPAP) and mean systemic arterial pressures (MSAP) were determined by electrical dampening. Heart rate (HR) was determined from a standard ECG lead which was monitored continuously. Pressures and ECGs were recorded on a multichannel photographic recorder run at various paper speeds. Arterial oxygen saturations (AO2) and pulmonary oxygen saturations (PAO2) were determined in 17 patients by oximetry, using an American Optical oximeter. Arterial lactates were measured in 11 patients using enzymatic techniques. 3 The (19 patients) , between the 20 and 10 ,g/kg/min doses (19 patients) , between the 30 and 20 .Lg/kg/min doses (14 patients), between the 40 and 30 ug/kg/min doses (9 patients) and between the post-infusion and control measurements (16 patients). A P value > 0.05 was considered not significant (NS). In order to see whether progressive hemodynamic changes occurred during phentolamine infusion at a constant dose, measurements were made in six patients 15 minutes and 30 minutes after beginning the 10 ,g/kg/min phentolamine infusion. Hemodynamic measurements were also obtained in 16 of the 19 patients at an average of 53 minutes after the phentolamine infusion was discontinued.
Results
Mean and SEM for all measured parameters before, during and following phentolamine infusion are listed in table 1.
Control Measurements
Two sets of control measurements were obtained 15 minutes apart in 16 of the 19 patients. There were no significant differences between the two measurements for any parameter. In all 19 patients, control CI was reduced (< 2.6 I/min/M2, average 1.9 I/min/m2), and LVFP was increased (. 12 mm Hg, average 19 mm Hg).
Response to Phentolamine Dose-Response Relationships All 19 patients were studied during both the 10 ,ug/kg/min (P-IO) and 20 ,ug/kg/min (P-20) infusions. At the P-10 infusion, significant (P < 0.001) decreases in both left-and right-sided pressures occurred with MSAP falling from 83 ± 3 mm Hg to 77 ± 3% mm Hg, MPAP from 42 ± 3 mm Hg to 35 ± 2 mm Hg and LVFP from 25 ± 2 mm Hg to 19 ± 2 mm Hg.
Coincident with the fall in pressures, CI increased from 1.9 ± 0.1 1/min/m2 to 2.8 ± 0.2 1/min/M2, and AO2-PAO2 difference decreased from 45 ± 3 to 28 ± 2% (P < 0.001). HR was also significantly increased from 87 ± 3 beats/min to 94 + 3 beats/min (P < 0.001), and thus increases in stroke volume (SV) and LVSWI, although significant at the 0.001 level, were of lesser magnitude than the increases in CI.
Values obtained during the P-20 infusion, when compared with those obtained during the P-10 infusion, showed further significant reduction in all pressures except for ASP, with MSAP falling to 74 ± 3 mm Hg (P < 0.01), MPAP falling to 32 ± 3 mm Hg (P < 0.01) and LVFP falling to 17 ± 2 mm Hg LVFP = left ventricular filling pressure; RAP = right atrial pressure; HR = heart rate; CI = cardiac index; SI = stroke index; LVSWI = left ventricular stroke work index; SAR = systemic arteriolar resistance; PAR = pulmonary arteriolar resistance; A02 = arterial oxygen saturation; PA02 = pulmonary artery oxygen saturation.
(P < 0.02). Although at P-20, CI was further increased to 3.0 ± 0.2 I/min/M2, this value was not significantly different than at the P-10 dose. At P-20, HR which averaged 98 ± 3 beats/min was, however, significantly increased (P < 0.05) from the P-10 value.
Fourteen patients were studied at the 30 ,g/kg/min (P-30) dosage, and these values were compared to values present at the P-20 level in these patients. Except for ASP and ADP, there were no further significant changes in any of the parameters between the P-20 and P-30 dose levels.
Nine patients were studied at all four dose levels, and values during control and each dose level for these patients are illustrated in figures 1-6. None of the parameters measured at 40 ,ug/kg/min (P-40) was significantly changed from values obtained at the P-30 infusion rate in these patients.
Arterial lactate was normal during the control and did not change significantly throughout the study. In 16 patients, measurements were obtained an average of 53 ± 3 minutes after phentolamine had been stopped. As can be seen in figure 7 , the major effect of phentolamine appeared to persist throughout this post-infusion period, and hemodynamics remained significantly altered from control values. Although the use of both phenoxybenzamine and chlorpromazine can result in desirable hemodynamic effects, phentolamine offers certain advantages over these agents because of its relatively short duration of action and absence of central nervous system depression.
Discussion
The effectiveness of phentolamine in improving hemodynamics in patients with severe heart failure has been documented by several investigators. Majid, Sharma and Taylor6 studied 12 patients with ischemic heart disease treated with phentolamine for three hours at a dose level of 1-2 mg/min. Patients were divided into two groups: those with incapacitating heart failure (six patients) and those with less severe heart failure (six patients). In both groups, phentolamine infusion was associated with significant improvement in CO and reduction in LVFP. Kelly et al. 7 reported hemodynamic effects of phentolamine infused at a dose of 0.75-1.5 mg/min in 11 Our own data confirm that of the above investigators. In our patients, we observed significant improvement in CI and reduction in LVFP within 15 minutes after starting phentolamine infusion at a dose of 10 ,ug/kg/min (equivalent to an infusion rate of 0.8 mg/min for an 80 kg patient). Although statistically significant additional reductions in left-and rightsided pressures and increases in heart rate were observed when the infusion rate was raised from [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] ,ug/kg/min, the magnitude of these changes was small compared to changes present at the initial 10 ,ug/kg/min dose. Further significant hemodynamic changes were not seen at the higher infusion rates of 30 or 40 jig/kg/min. Measurements adverse effect on coronary collateral function18 and may increase the degree of ischemic injury induced by coronary constriction."9 However, since hemodynamic and metabolic improvement has been observed with both phentolamine and nitroprusside in patients with heart failure due to coronary artery disease, the clinical implication of these experimental investigations is uncertain.
Our studies, although limited to patients with stable chronic heart failure, showed that phentolamine was an effective agent for temporarily improving hemodynamics in such patients. We have not studied phentolamine in acute heart failure, but others8 have reported favorable results in patients with acute pulmonary edema. Although the effects of phentolamine in patients who fail to respond adequately to sodium nitroprusside has not been defined, such a trial would seem to be indicated. In addition, phentolamine might be a reasonable alternative to nitroprusside in patients with heart failure when the required duration of therapy or nitroprusside dosage is likely to result in thiocyanate toxicity. Presently, the cost and availability of intravenous phentolamine, which is supplied as 5 mg ampules in lyphilized form, make it an expensive and cumbersome agent to administer by continuous infusion over several hours or days. The role of phentolamine in the future management of patients with severe heart failure has not been determined.
